Sitravatinib

Drug Profile

Sitravatinib

Alternative Names: MG-516; MG91516; MGCD-516

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MethylGene
  • Developer Columbia University; Mirati Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE 2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liposarcoma; Non-small cell lung cancer; Soft tissue sarcoma
  • Phase I/II Renal cell carcinoma
  • Phase I Solid tumours

Most Recent Events

  • 14 Sep 2017 Adverse events and efficacy data from a phase Ib case study in Solid tumours released by Mirati Therapeutics
  • 14 Sep 2017 Adverse events and efficacy data from a phase II trial in Non-small cell lung cancer released by Mirati Therapeutics
  • 14 Sep 2017 Pharmacodynamics data from a preclinical trial in Solid tumours (NSCLC) released by Mirati Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top